Table 3

Skin infections in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

Time to event


Infection

No. of events

Median

Range

Druga (no.)

Active treatmentb (no.)

Rechallenge (no.)

Permanent withdrawal of anti-TNF-αc (no.)

Biopsy (no.)

Cultured species


Fungal

20

8.7

1.1–61.1

Dermatomycosis

9

A 3, I 4, E 2

7

0

1

Trichophyton verrucosum (1) T. rubrum (1)

Onychomycosis

3

A 3

3

0

0

Combination

5

A 3, I 1, L 1

4

0

1

Trichophyton rubrum (3) T. mentagrofytes (1)

Candidiasis

3

I 3

2

0

0

Candida spp. (2)

Bacterial

11

9.5

1.4–52.5

Folliculitis

5

A 3, E 2

4

yes, negative

1

2

Staphylococcus aureus (1)

Erysipelas

3

E 2, I 1

3

yes, negative

2

1

Bacterial superinfection of eczema

2

A 1, I 1

1

yes, positive

1

0

Furuncle

1

I 1

0

0

0

Viral – herpes zoster

2

17.3, 40.9d

A 1, I 1

0

0

0


aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bDuring active treatment with TNF-α-blocking therapy. cPermanent discontinuation of TNF-α-blocking therapy due to the event.d Individual values

Flendrie et al. Arthritis Research & Therapy 2005 7:R666-R676   doi:10.1186/ar1724

Open Data